{"id":4821,"date":"2025-10-03T11:47:49","date_gmt":"2025-10-03T02:47:49","guid":{"rendered":"https:\/\/bionauts.jp\/?p=4821"},"modified":"2025-10-08T18:34:56","modified_gmt":"2025-10-08T09:34:56","slug":"acute-myeloid-leukemia-aml-treatment","status":"publish","type":"post","link":"https:\/\/bionauts.jp\/?p=4821","title":{"rendered":"Acute Myeloid Leukemia (AML) Treatment"},"content":{"rendered":"<h3>Advantages<\/h3>\n<ul>\n<li>More effective companion diagnostics and therapeutic agents for FLT3 inhibitor-resistant AML.<\/li>\n<\/ul>\n<h3>Current Stage and Key Data<\/h3>\n<p>We have identified FLT3 inhibitor resistance markers and candidate resistance-improving agents, and confirmed their effectiveness in a human leukemia cell model.<\/p>\n<ul>\n<li>PDX mouse models were created by transplanting bone marrow cells collected from FLT3 gene mutation-positive AML patients. We identified a group of molecules that were more highly expressed in leukemia cells remaining after long-term daily administration of FLT3 inhibitors (resistance-acquired) than before administration (top figure).<\/li>\n<li>High expression of the same group of molecules was also confirmed in the FLT3 mutant human leukemia cell line MOLM14, which had acquired resistance.<\/li>\n<li>Increased expression of one of the molecules in the same group was observed in patient cells that had clinically become resistant to FLT3 inhibitor treatment.<\/li>\n<li>In resistant MOLM14, the same group of molecules was inhibited with a candidate resistance-improving agent. Sensitivity to FLT3 inhibitors was restored (bottom figure).<\/li>\n<\/ul>\n<table style=\"border-collapse: collapse; width: 53%; height: 278px;\">\n<tbody>\n<tr>\n<td style=\"width: 100%;\"><a href=\"http:\/\/bionauts.jp\/wp-content\/uploads\/2025\/10\/BK-05208_lower_EN.png\"><img decoding=\"async\" loading=\"lazy\" class=\"alignleft wp-image-4822 size-full\" src=\"http:\/\/bionauts.jp\/wp-content\/uploads\/2025\/10\/BK-05208_lower_EN.png\" alt=\"\" width=\"307\" height=\"413\" srcset=\"https:\/\/bionauts.jp\/wp-content\/uploads\/2025\/10\/BK-05208_lower_EN.png 307w, https:\/\/bionauts.jp\/wp-content\/uploads\/2025\/10\/BK-05208_lower_EN-223x300.png 223w\" sizes=\"(max-width: 307px) 85vw, 307px\" \/><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Partnering Model<\/h3>\n<p>We are seeking partnerships with companies focused on the development of AML diagnostics and treatments, and are open to collaborative research and commercial licensing.<\/p>\n<ul>\n<li>Examples of potential partners: Pharmaceutical\/biotech companies and diagnostic companies focused on developing and providing treatments for blood cancer and AML, as well as FLT3 inhibitors.<\/li>\n<\/ul>\n<h3>Background<\/h3>\n<p>Constitutively active mutations in the FLT3 (Fms-Like Tyrosine Kinase 3) gene are a poor prognostic factor found in approximately 20% of acute myeloid leukemia (AML). For this reason, various FLT3 inhibitors are used to treat AML; however, resistance to FLT3 inhibitor therapy can develop relatively quickly. For example, in clinical trials of the FLT3 inhibitor gilteritinib in relapsed\/refractory FLT3 mutation-positive AML, median survival was reported to be only 9.3 months with gilteritinib treatment, compared with 5.6 months with salvage chemotherapy, highlighting the short duration of response to FLT3 inhibitors.<\/p>\n<h3>Patents and Publications<\/h3>\n<ul>\n<li>Paper submission in preparation, patent pending (unpublished).<\/li>\n<\/ul>\n<h3>Principal Investigator<\/h3>\n<p>Professor Hitoshi KIYOI (Graduate School of Medicine, Nagoya University, Tokai National Higher Education and Research System)<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>Project ID:BK-05208<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Marker molecules showing resistance to FLT3 inhibitors in FLT3-mutated AML cells, and FLT3 inhibitor sensitizers targeting these molecules.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"categories":[1],"tags":[],"categories_of_inventions":[46],"disease_categories___indication":[],"asset_type":[],"development_phase":[],"medicine":[102,103],"other_than_medicine":[],"material":[],"engineering":[],"software_it":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/posts\/4821"}],"collection":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4821"}],"version-history":[{"count":2,"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/posts\/4821\/revisions"}],"predecessor-version":[{"id":4824,"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/posts\/4821\/revisions\/4824"}],"wp:attachment":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4821"},{"taxonomy":"categories_of_inventions","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories_of_inventions&post=4821"},{"taxonomy":"disease_categories___indication","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fdisease_categories___indication&post=4821"},{"taxonomy":"asset_type","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fasset_type&post=4821"},{"taxonomy":"development_phase","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fdevelopment_phase&post=4821"},{"taxonomy":"medicine","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedicine&post=4821"},{"taxonomy":"other_than_medicine","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fother_than_medicine&post=4821"},{"taxonomy":"material","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmaterial&post=4821"},{"taxonomy":"engineering","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fengineering&post=4821"},{"taxonomy":"software_it","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fsoftware_it&post=4821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}